CONSALVI SILVIA, Curriculum Vitae

Informazioni Personali

Nome e Cognome: Silvia Consalvi
Data e luogo di nascita: 17/08/1984 Marino (RM), Italia

Istruzione e formazione

2009 – 2013	PhD in Biologia Cellulare e Molecolare, Università Tor Vergata, Roma, Italia.
2009 – 2010	Studente PhD ospite presso SanfordIBurnham Medical Research Institute, San Diego, California, USA.
2006 – 2009	Laurea specialistica (110/110 cum laude) in Biologia Cellulare e Molecolare, Università Tor Vergata, Roma, Italia.
2003 – 2006	Laurea triennale (110/110 cum laude) in Biologia Cellulare e Molecolare, Università Tor Vergata, Roma, Italia.

Esperienze professionali

2018 – ora	Ricercatore Responsabile presso IRCCS Fondazione Santa Lucia, Roma, Italia.
2013 – 2018	Ricercatore Post dottorato presso IRCCS Fondazione Santa Lucia, Roma, Italia.
2016 – 2018	Ricercatore Post dottorato ospite presso Sanford-Burnham-Prebys Medical Discovery Institute, San Diego, California, USA

Abilitazioni professionali

2018	Abilitazione Professore Universitario di II fascia in Patologia Generale e Patologia Clinica.
2018	Abilitazione Professore Universitario di II fascia in Biologia Cellulare e Molecolare.
2018	Abilitazione Professore Universitario di II fascia in Biologia Applicata.
2012	Iscrizione Ordine Nazionale dei Biologi (ONB).
2010	Esame di Stato Biologo.

Aree di ricerca

Biologia cellulare e molecolare; segnalazione cellulare; studi NGS; cellule staminali; medicina rigenerativa; farmacologia epigenetica; malattie neuromuscolari.

Lista di pubblicazioni

1. Sandoná M**, Consalvi S***, Tucciarone L, De Bardi M, Scimeca M, Angelini DF, Buffa V, D'Amico A, Bertini ES, Cazzaniga S, Bettica P, Bouchè M, Bongiovanni A, Puri PL, Saccone V. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells. EMBO Rep. 2020; e50863.
2. Iannotti FA, Pagano E, Guardiola O, Adinolfi S, Saccone V, **Consalvi S**, Piscitelli F, Gazzerro E, Busetto G, Carrella D, Capasso R, Puri PL, Minchiotti G, Di Marzo V. Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nature Comm. 2018; 9(1):3950.
3. Marroncelli N, Bianchi M, Bertin M, **Consalvi S**, Saccone V, De Bardi M, Puri PL, Palacios D, Adamo S. HDAC4 regulates satellite cell proliferation and differentiation by targeting P21 and Sharp1 genes. Sci Rep. 2018; 8 (1): 3448.
4. Tucciarone L, Etxaniz U, Sandoná M, **Consalvi S#**, Puri PL, Saccone V. Advanced methods to study the cross-talk between Fibro-adipogenic Progenitors and Muscle Stem Cells. Methods in Mol Biol 2018; 231-256. **# Co-Corresponding author.**
5. **Consalvi S**, Brancaccio A, Dall'Agnese A, Puri PL, Palacios D. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation. Nature Comm. 2017; 8:13956. **First author**.
6. **Consalvi S**, Sandoná M, Saccone V. Epigenetic Reprogramming of Muscle Progenitors: Inspiration for Clinical Therapies. Stem Cells International 2016; 2016:6093601. **First author**.
7. Sandoná M, **Consalvi S**, Tucciarone L, Puri PL, Saccone V. HDAC inhibitors for muscular dystrophies: progress and prospects. HDAC inhibitors for muscular dystrophies: progress and prospects. Expert Opinion on Orphan Drugs 2016; 4 (2), 125-127.
8. Giordani L, Sandoná M, Rotini A, Puri PL, **Consalvi S$^{\#}$**, Saccone V$^{\#}$. Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. Rare Diseases 2014; 2 (1), e974969. **# Co-Corresponding author.**
9. **Consalvi S**, Saccone V, Mozzetta C. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. Epigenomics 2014; 6 (5), 547-560. **First author**.
10. Saccone V*, **Consalvi S***, Giordani L, Mozzetta C, Barozzi I, Sandonà M, Ryan T, Rojas Munoz A, Madaro L, Fasanaro P, Borsellino G, De Bardi M, Frigè GM, Termanini A, Sun X, Rossant J, Bruneau B, Mercola M, Minucci S, Puri PL. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes & development 2014; 28 (8), 841-857. *** Co-First author.**
11. Marroncelli N, Noviello C, **Consalvi S**, Saccone V, Puri PL, Olson EN, Adamo S, Moresi V. HDAC4 is necessary for satellite cell differentiation and muscle regeneration. Italian Journal of Anatomy and Embryology 2014;119 (1), 126.
12. **Consalvi S,** Mozzetta C, Bettica P, Germani M, Fiorentini F, Rocchetti M, Leoni F., Modena D, Monzani V, Fossati G, Mascagni P, Puri PL, Saccone S. Preclinical studies with pharmacological treatment of murine model of Duchenne Muscular Dystrophy with the Histone Deacetylase inhibitor Givinostat. Mol Med. 2013;19:79-87. **First author**.
13. Mozzetta C*, **Consalvi S***, Saccone V, Tierney M, Diamantini A, Mitchel KJ, Marazzi G, Borsellino G, Battistini L, Sassoon D, Sacco A, Puri PL. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in

dystrophic muscles of young, but not old mdx mice. EMBO Mol Med. 2013;5(4):626-39. *** Co-First author.**

14. **Consalvi S**, Mozzetta C, Bettica P, Mascagni P, Monzani V, Germani M, Del Bene F, Puri PL, Saccone V.TP 2 Givinostat improves histological and functional parameters in mdx mice dose and concentration dependently. Neuromuscular Disorders, 2012;22 (9), 847. **First author**.
15. Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A, Coutinho P, Saccone V, **Consalvi S**, Williams R, Wang K, Wu Z, Baranovskaya S, Miller A, Dilworth FJ, Puri PL. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J. 2012;31(2):301-16.
16. **Consalvi S**, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol Med. 2011;17(5-6):457-65. **First author**.
17. Mozzetta C*, **Consalvi S***, Saccone V, Forcales SV, Puri PL, Palacios D. Selective control of Pax7 expression by TNF-activated p38α/polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. Cell Cycle. 2011;10(2):191-8. *** Co-First author**.
18. Palacios D, Mozzetta C, **Consalvi S**, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, Sartorelli V, Puri PL. TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell. 2010;7(4):455-69.

Brevetti

Saccone V, **Consalvi S**, Puri PL, Mascagni P. Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl- methyl]-ammonium chloride for use in the treatment of muscular dystrophy. US Patent 9,421,184, 2016.

Premi e Grants

2009: Premio "Sebastiano e Rita Raeli" per i migliori studenti laureati dell'Università Tor Vergata.

2009: Borsa di Dottorato Telethon.

2016: Epigen travel grant, per svolgere formazione e attività di ricerca all'estero presso Institute for Genomic medicine, University of California, San Diego, USA. Titolo: HiC-mediated discovery of long-range interactions between genomic loci of primary muscle-derived interstitial cells.

2018: Borsa Post dottorato Afm Telethon. Titolo: Exosome-mediated HDACi/miR-143/STAT3 network in the regulation of satellite cells expansion and muscle regeneration.

2018: Grant Giovani Ricercatori, Ministero della Salute. Ruolo: Co-Principal Investigator. Titolo: Regenerative potential of Fibro-Adipogenic Progenitors derived exosomes in the treatment of Duchenne Muscular Dystrophy with Histone Deacetylase Inhibitors.

2018: Grant Parent Project Onlus. Ruolo: Principal Investigator. Titolo: Metabolic reprogramming: a novel therapeutic strategy for Duchenne Muscular Dystrophy.

2018: Premio "Luigi Amadio" come miglior giovane ricercatore presso IRCCS Fondazione Santa Lucia, Roma, Italia.